康莱特治疗非小细胞肺癌恶性胸腔积液的临床观察  

The Clinical Observation of Malignant Pleural Effusion in Nonsmall-cell Lung Cancer through Kanglaite

作　　者：李惠华[1] 刘亮[1] 张弛[1] 刘洪[1] 

机构地区：[1]四川成都市第一人民医院呼吸内科第二病区,四川成都610016

出　　处：《中国医药指南》2012年第21期438-439,共2页Guide of China Medicine

摘　　要：目的观察康莱特联合顺铂治疗非小细胞肺癌恶性胸腔积液近期疗效和毒副作用。方法 60例非小细胞肺癌恶性胸腔积液患者随机分为实验组与对照组各30例。其中对照组胸腔内灌注顺铂,实验组胸腔内灌注康莱特加顺铂,1个月后观察两组的疗效及不良反应。结果康莱特加顺铂对非小细胞肺癌恶性胸腔积液的有效率为86.6%,优于顺铂单用组。结论康莱特治疗非小细胞肺癌恶性胸腔积液疗效肯定,是控制非小细胞肺癌恶性胸腔积液的有效方法。Objective To investigate the curative efficacy and adverse reaction of Kanglaite associated with cis-DDP on malignant pleural effusion in NSCLC. Methods 60 patients were randomly divided into the treatment group and the control group. The control group was given with cis-DDP; the treatment group was given with Kanglaite in additional based on the control group. Then to observe and analyse the curative efficacy and adverse reaction. Results The effective power of the treatment group is 86.6%, better than the control group. Conclusion It is an effective treatment of Kanglaite for malignant pleural effusion in NSCLC.

关 键 词：非小细胞肺癌 恶性胸腔积液 康莱特 

分 类 号：R734.2[医药卫生—肿瘤]